Longitudinal Anti-Inflammaging Study
Overview
The Longitudinal Anti-Inflammaging Study is an early-phase clinical trial designed to evaluate the safety, tolerability, and biological effects of dietary supplements and other interventions targeting the aging process. The first cohort focuses on spermidine — a naturally occurring compound found in foods like wheat germ, soy, and miso — investigating its effects on immune and metabolic function across escalating doses.
The study is being conducted at the Atria Health and Research Institute in New York City, in collaboration with researchers from the Icahn School of Medicine at Mount Sinai.
Study Leaders
Co-Investigators at the Atria Global Health and Research Institute
Dr. David Dodick — Dr. David Dodick is Chief Science & Medical Officer at Atria and Co-Director of Atria Research Institute. He is a top neurologist, and prior to joining Atria, he was an esteemed faculty member of the Mayo Clinic for more than 30 years. He has authored 13 books and more than 900 peer-reviewed abstracts and manuscripts.
Dr. Gregory Poland — Dr. Poland is Co-Director of the Atria Research and Global Health Institute and Chief Innovation Officer of Atria Health Institute. He is a physician and vaccine expert who has served for more than 30 years at Mayo Clinic, where he runs the Vaccine Research Group.
Dr. Louis DePalo — Dr. Louis DePalo is a top internal medicine doctor and sought-after pulmonology expert with an extensive background in research and clinical care. As the former director of a prestigious lung transplant program at Mount Sinai, he has dedicated much of his career to unraveling the complexities of the human body. He is Medical Director of Atria New York.
Collaborators
Dr. Miriam Merad, MD, PhD — Dr. Merad leads the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai, where her work focuses on translating immunology discoveries into clinical research. She is a Top 40 Milestone Award winner in the XPRIZE Healthspan, a $101 million global competition advancing research on aging and healthspan science.
Dr. Thomas Marron, MD, PhD — Director of the Early Phase Trials Unit at The Tisch Cancer Institute and Professor of Immunology and Immunotherapy at the Icahn School of Medicine at Mount Sinai. Also a Top 40 Milestone Award winner in the XPRIZE Healthspan competition.
Impact
Aging is not a single event—it is a process, shaped by chronic, low-grade inflammation that accumulates over time and underlies many of the diseases we associate with growing older. Understanding how to slow or interrupt that process could reshape what it means to age well.
Spermidine has attracted scientific attention for its potential to do just that. Found naturally in the body and in common foods, it plays a key role in autophagy—the cellular process by which the body clears damaged cells and maintains function. In laboratory studies, spermidine has been linked to improved cardiovascular health, reduced inflammation, better immune function, enhanced lipid metabolism, and improved aerobic performance.
The question this study is designed to answer: what does it do in humans, at what dose, and how do we measure it?
Current Work
The first cohort of the study is currently underway with ten research participants. This open-label, dose-escalation trial is evaluating Sprevive®—a pure spermidine formulation developed by Chrysea Labs—with a focus on characterizing dose-response relationships in biomarkers related to immune and metabolic function.
Future Work
The study is designed to expand beyond spermidine. With additional funding and resources, subsequent cohorts will assess the safety and effectiveness of multiple other dietary supplements and aging-targeted interventions — building a rigorous, human-centered evidence base for the science of healthy longevity.
Partners and Collaborators
Icahn School of Medicine at Mount Sinai · Chrysea Labs · XPRIZE Healthspan